guidanc cut put merck
lower outlook cloud bull case
merck lower outlook revenu ep stand biopharma
moder weaken defens case sector view said
reveal risk concentr growth oncology/vaccin merck-
specif amplifi post propos spin rel peer merck
appear respond pandem slower oper base
comment today addit given merck expertis vaccines/antivirals/antibodi
develop also expect leader laggard emerg
drug pipelin mean stock first think
share benefit less industri halo pipelin visibl
second suspect generalist investor less like put defens
categori versu lly/pfe/vrtx even even new guidanc prove conserv
full normal weight toward re-rat justifi vs
biopharma peer especi go spin neg impact
revenu growth beyond guidanc call focus pipelin asset outsid
keytruda includ lenvima vericiguat commentari larg in-lin
recent cfo call continu like merck core i/o busi overal today
updat along announc spin could weigh sentiment nt lower
po prior reflect today updat reiter neutral
heighten concern growth profil linger
wouldnt surpris see merck outlook improv unfold today
updat shift convers above-p growth modestli
revenue ep midpoint vs con head
see case upsid long-term investor much focus
expect concern linger time near next year controversi spin-off
still expect given near-term optic slower growth busi model
revenue ep growth revenue ep
model chang pro forma expect revenu ep
ep page addit detail model chang
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
merck co global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
remain posit overal merck stori
howev neutral thesi reflect
moment rise expect
keytruda franchis expect
keytruda maintain domin posit
across i/o landscap year come see
littl room upsid current street
expect larg major higher-
impact catalyst play
million
price object po base combin intrins valu remainco
newco valu remainco base
blend averag price-to-earnings multipl appli ep reflect continu
strength merck core growth franchis risk-adjust dcf wacc
termin growth rate valu newco base assum ev/ebitda
first full year repres discount vs peer reflect slow growth
risk po impress competitor readout result key i/o indic
nsclc rcc rapid declin across diabet franchis
expect neg outcom compani later-stag asset on-going
develop pressur headlin risk face sector includ drug price
reform spin-off take place
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
